Other studies have suggested that CD38 is only minimally expressed on normal lymphocytes or bone marrow cells, but is highly expressed on the surface of myeloma cells, so the CD38 molecule may be a new target for MM therapy [132, 133]. This evidence concerns the gene CD38 and Miyoshi myopathy.